FGFR2 (V564F)
Sign in to save this workspaceFGFR2 · Variant type: point · HGVS: p.V564F
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Sunitinib | 98.8% | 1.2% | 91.73 |
| 2 | Selpercatinib | 98.5% | 1.5% | 96.72 |
| 3 | Brigatinib | 98.5% | 1.5% | 82.96 |
| 4 | Defactinib | 98.2% | 1.8% | 92.68 |
| 5 | Entrectinib | 97.0% | 3.0% | 93.69 |
| 6 | Pralsetinib | 97.0% | 3.0% | 93.43 |
| 7 | Nintedanib | 96.9% | 3.1% | 90.23 |
| 8 | Ponatinib | 94.7% | 5.3% | 78.23 |
| 9 | Pacritinib | 94.0% | 6.0% | 88.64 |
| 10 | Repotrectinib | 93.0% | 7.0% | 84.21 |
| 11 | Fedratinib | 90.8% | 9.2% | 96.21 |
| 12 | Axitinib | 89.4% | 10.6% | 93.23 |
| 13 | Avapritinib | 85.3% | 14.7% | 97.73 |
| 14 | Pexidartinib | 81.5% | 18.5% | 99.49 |
| 15 | Ibrutinib | 77.2% | 22.8% | 94.74 |
| 16 | Sorafenib | 77.2% | 22.8% | 96.72 |
| 17 | Gilteritinib | 75.5% | 24.5% | 88.97 |
| 18 | Alpelisib | 75.2% | 24.8% | 97.22 |
| 19 | Crizotinib | 73.0% | 27.0% | 91.39 |
| 20 | Upadacitinib | 72.6% | 27.4% | 97.98 |
| 21 | Alectinib | 72.0% | 28.0% | 95.49 |
| 22 | Tenalisib | 70.2% | 29.9% | 97.98 |
| 23 | Fostamatinib | 69.9% | 30.1% | 96.74 |
| 24 | Futibatinib | 66.2% | 33.8% | 98.48 |
| 25 | Canertinib | 65.2% | 34.8% | 96.49 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Sunitinib | 98.8% | — | — |
| Selpercatinib | 98.5% | 95.0% | +3.5% |
| Brigatinib | 98.5% | 96.1% | +2.4% |
| Defactinib | 98.2% | — | — |
| Entrectinib | 97.0% | 81.5% | +15.5% |
| Pralsetinib | 97.0% | 93.2% | +3.8% |
| Nintedanib | 96.9% | 97.0% | -0.1% |
| Ponatinib | 94.7% | 99.4% | -4.7% |
| Pacritinib | 94.0% | — | — |
| Repotrectinib | 93.0% | 79.8% | +13.1% |
| Fedratinib | 90.8% | — | — |
| Axitinib | 89.4% | 96.1% | -6.7% |
| Avapritinib | 85.3% | — | — |
| Pexidartinib | 81.5% | — | — |
| Ibrutinib | 77.2% | — | — |
| Sorafenib | 77.2% | — | — |
| Gilteritinib | 75.5% | — | — |
| Alpelisib | 75.2% | 98.9% | -23.7% |
| Crizotinib | 73.0% | — | — |
| Upadacitinib | 72.6% | — | — |
| Alectinib | 72.0% | — | — |
| Tenalisib | 70.2% | 96.0% | -25.8% |
| Fostamatinib | 69.9% | — | — |
| Futibatinib | 66.2% | 99.3% | -33.1% |
| Canertinib | 65.2% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_biliary_tract | Biliary Tract | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 18.3ms